QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
Lead exposure testing failures land Bendigo lab $10K fine
The laboratory pleaded guilty to failing to arrange for biological monitoring of two workers...
AI and deep-tech research program receives $400K grant
A program designed to help scientists transform AI and deep-tech research into commercially...
Australia–Vietnam collaborative research projects — applications open
Until 20 July, grant applications for projects in recycling and waste management, a sustainable...
